Effectiveness of Florbetapir PET Imaging in Changing Patient Management.

Published

Journal Article

AIMS: To evaluate the impact of amyloid PET imaging on diagnosis and patient management in a multicenter, randomized, controlled study. METHODS: Physicians identified patients seeking a diagnosis for mild cognitive impairment or dementia, possibly due to Alzheimer disease (AD), and recorded a working diagnosis and a management plan. The patients underwent florbetapir PET scanning and were randomized to either immediate or delayed (1-year) feedback regarding amyloid status. At the 3-month visit, the physician updated the diagnosis and recorded a summary of the actual patient management since the post-scan visit. The study examined the impact of immediate versus delayed feedback on patient diagnosis/management at 3 and 12 months. RESULTS: A total of 618 subjects were randomized (1:1) to immediate or delayed feedback arms, and 602 subjects completed the 3-month primary endpoint visit. A higher proportion of patients in the immediate feedback arm showed a change in diagnosis compared to the controls (32.6 vs. 6.4%; p = 0.0001). Similarly, a higher proportion of patients receiving immediate feedback had a change in management plan (68 vs. 55.5%; p < 0.002), mainly driven by changes in AD medication. Specifically, acetylcholinesterase inhibitors were prescribed to 67% of the amyloid-positive and 27% of the amyloid-negative subjects in the information group compared with 56 and 43%, respectively, in the control group (p < 0.0001). These between-group differences persisted until the 12-month visit. CONCLUSION: Knowledge of the amyloid status affects the diagnosis and alters patient management.

Full Text

Duke Authors

Cited Authors

  • Pontecorvo, MJ; Siderowf, A; Dubois, B; Doraiswamy, PM; Frisoni, GB; Grundman, M; Nobili, F; Sadowsky, CH; Salloway, S; Arora, AK; Chevrette, A; Deberdt, W; Dell'Agnello, G; Flitter, M; Galante, N; Lowrey, MJ; Lu, M; McGeehan, A; Devous, MD; Mintun, MA

Published Date

  • 2017

Published In

Volume / Issue

  • 44 / 3-4

Start / End Page

  • 129 - 143

PubMed ID

  • 28787712

Pubmed Central ID

  • 28787712

Electronic International Standard Serial Number (EISSN)

  • 1421-9824

Digital Object Identifier (DOI)

  • 10.1159/000478007

Language

  • eng

Conference Location

  • Switzerland